Tags

Type your tag names separated by a space and hit enter

Alternate day fasting for weight loss in normal weight and overweight subjects: a randomized controlled trial.
Nutr J. 2013 Nov 12; 12(1):146.NJ

Abstract

BACKGROUND

Alternate day fasting (ADF; ad libitum "feed day", alternated with 25% energy intake "fast day"), is effective for weight loss and cardio-protection in obese individuals. Whether these effects occur in normal weight and overweight individuals remains unknown. This study examined the effect of ADF on body weight and coronary heart disease risk in non-obese subjects.

METHODS

Thirty-two subjects (BMI 20-29.9 kg/m2) were randomized to either an ADF group or a control group for 12 weeks.

RESULTS

Body weight decreased (P < 0.001) by 5.2 ± 0.9 kg (6.5 ± 1.0%) in the ADF group, relative to the control group, by week 12. Fat mass was reduced (P < 0.001) by 3.6 ± 0.7 kg, and fat free mass did not change, versus controls. Triacylglycerol concentrations decreased (20 ± 8%, P < 0.05) and LDL particle size increased (4 ± 1 Å, P < 0.01) in the ADF group relative to controls. CRP decreased (13 ± 17%, P < 0.05) in the ADF group relative to controls at week 12. Plasma adiponectin increased (6 ± 10%, P < 0.01) while leptin decreased (40 ± 7%, P < 0.05) in the ADF group versus controls by the end of the study. LDL cholesterol, HDL cholesterol, homocysteine and resistin concentrations remained unchanged after 12 weeks of treatment.

CONCLUSION

These findings suggest that ADF is effective for weight loss and cardio-protection in normal weight and overweight adults, though further research implementing larger sample sizes is required before solid conclusion can be reached.

Authors+Show Affiliations

Department of Kinesiology and Nutrition, University of Illinois at Chicago, 1919 West Taylor Street, Room 506 F, Chicago, IL 60612, USA. varady@uic.edu.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24215592

Citation

Varady, Krista A., et al. "Alternate Day Fasting for Weight Loss in Normal Weight and Overweight Subjects: a Randomized Controlled Trial." Nutrition Journal, vol. 12, no. 1, 2013, p. 146.
Varady KA, Bhutani S, Klempel MC, et al. Alternate day fasting for weight loss in normal weight and overweight subjects: a randomized controlled trial. Nutr J. 2013;12(1):146.
Varady, K. A., Bhutani, S., Klempel, M. C., Kroeger, C. M., Trepanowski, J. F., Haus, J. M., Hoddy, K. K., & Calvo, Y. (2013). Alternate day fasting for weight loss in normal weight and overweight subjects: a randomized controlled trial. Nutrition Journal, 12(1), 146. https://doi.org/10.1186/1475-2891-12-146
Varady KA, et al. Alternate Day Fasting for Weight Loss in Normal Weight and Overweight Subjects: a Randomized Controlled Trial. Nutr J. 2013 Nov 12;12(1):146. PubMed PMID: 24215592.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Alternate day fasting for weight loss in normal weight and overweight subjects: a randomized controlled trial. AU - Varady,Krista A, AU - Bhutani,Surabhi, AU - Klempel,Monica C, AU - Kroeger,Cynthia M, AU - Trepanowski,John F, AU - Haus,Jacob M, AU - Hoddy,Kristin K, AU - Calvo,Yolian, Y1 - 2013/11/12/ PY - 2013/07/03/received PY - 2013/11/04/accepted PY - 2013/11/13/entrez PY - 2013/11/13/pubmed PY - 2014/9/4/medline SP - 146 EP - 146 JF - Nutrition journal JO - Nutr J VL - 12 IS - 1 N2 - BACKGROUND: Alternate day fasting (ADF; ad libitum "feed day", alternated with 25% energy intake "fast day"), is effective for weight loss and cardio-protection in obese individuals. Whether these effects occur in normal weight and overweight individuals remains unknown. This study examined the effect of ADF on body weight and coronary heart disease risk in non-obese subjects. METHODS: Thirty-two subjects (BMI 20-29.9 kg/m2) were randomized to either an ADF group or a control group for 12 weeks. RESULTS: Body weight decreased (P < 0.001) by 5.2 ± 0.9 kg (6.5 ± 1.0%) in the ADF group, relative to the control group, by week 12. Fat mass was reduced (P < 0.001) by 3.6 ± 0.7 kg, and fat free mass did not change, versus controls. Triacylglycerol concentrations decreased (20 ± 8%, P < 0.05) and LDL particle size increased (4 ± 1 Å, P < 0.01) in the ADF group relative to controls. CRP decreased (13 ± 17%, P < 0.05) in the ADF group relative to controls at week 12. Plasma adiponectin increased (6 ± 10%, P < 0.01) while leptin decreased (40 ± 7%, P < 0.05) in the ADF group versus controls by the end of the study. LDL cholesterol, HDL cholesterol, homocysteine and resistin concentrations remained unchanged after 12 weeks of treatment. CONCLUSION: These findings suggest that ADF is effective for weight loss and cardio-protection in normal weight and overweight adults, though further research implementing larger sample sizes is required before solid conclusion can be reached. SN - 1475-2891 UR - https://www.unboundmedicine.com/medline/citation/24215592/Alternate_day_fasting_for_weight_loss_in_normal_weight_and_overweight_subjects:_a_randomized_controlled_trial_ L2 - https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-12-146 DB - PRIME DP - Unbound Medicine ER -